VPT:CC - Ventripoint to Sponsor Advanced Imaging 2023 in London England
(TheNewswire)
Toronto, Ontario – The Newswire –July 11, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company ") (TSXV:VPT ) ; ( OTC:VPTDF), is pleased to announce its participation as asponsor in Advanced Imaging 2023: Pericardial Disease, a prestigiousjoint meeting sponsored by the British Society of Echocardiography andthe Royal Society of Medicine. The event is scheduled to take placein London, England on July 18, 2023. The conference promises acomprehensive overview of multimodality imaging and intervention forpericardial disease. Ventripoint’s VMS+ solution provides physicianswith real-time volume data to monitor the treatment and progression ofpericardial disease.
This is Ventripoint’s inaugural attendance at thisconference as partner of the British Society of Echocardiography. The company is thrilled to be part of this esteemed gatheringalongside Ventripoint’s distribution partner, Cardiologic.Ventripoint looks forward to joining the conversation and showcasing our products alongside other cutting-edge solutions in cardiac imaging and interventionfor cardiac disease. We endeavor to partner withworld class physicians and hospitals alike to provide innovativediagnostic and treatment solutions that elevate cardiac care byimproving the patient experience.
Advanced Imaging 2023 serves as a unique platform whereleading professionals, researchers, and healthcare practitioners cancollaborate and exchange knowledge, advancements, and best practicesin the field of multimodality imaging and intervention for pericardialdisease. It is very important for pericardial disease to be detectedand managed with precise imaging in order to provide effectivetreatment. With the overarching goal of advancing patient care andcardiovascular health for pericardial disease, the conference offers adiverse program of lectures and interactive case discussions.
Ventripoint’s VMS+ family of products enable preciseand accurate volumetric analysis of the heart, providing insights forclinicians in diagnosing and monitoring cardiovascular diseases.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
JRobinson@oakhillfinancial.ca
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.